Using genomics to identify high-risk myeloma after autologous stem cell transplantation

被引:20
作者
Shaughnessy, JD [1 ]
Barlogie, B [1 ]
机构
[1] Univ Arkansas Med Sci, Donna D & Donald M Lambert Lab Myeloma Genet, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA
关键词
multiple myeloma; autologous stem cell transplantation; high-dose therapy; survival;
D O I
10.1016/j.bbmt.2005.10.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma is a malignancy of antibody-secreting plasma cells that expand in the bone marrow. Although high-dose therapy/autologous stem cell transplantation has become the standard of care for patients with multiple myeloma, survival is highly variable and can range from a few years to > 10 years after diagnosis. Application of high-throughput genomics on a large uniformly untreated cohort of patients has revealed that activation of I of the 3 cyclin D genes is a universal initiating event in this disease and that acquisition of abnormalities of chromosome 1 leads to activation of CKS1B, a regulator of p27Kip1 degradation. Synergy between cyclin D2 and CKS1B, but not cyclin D1 and CKS1B, may lead to early treatment failure. (C) 2006 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:77 / 80
页数:4
相关论文
共 42 条
[21]   Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma [J].
Kaufmann, H ;
Ackermann, J ;
Baldia, C ;
Nösslinger, T ;
Wieser, R ;
Seidl, S ;
Sagaster, V ;
Gisslinger, H ;
Jäger, U ;
Pfeilstöcker, M ;
Zielinski, C ;
Drach, J .
LEUKEMIA, 2004, 18 (11) :1879-1882
[22]   In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression [J].
Keats, JJ ;
Reiman, T ;
Maxwell, CA ;
Taylor, BJ ;
Larratt, LM ;
Mant, MJ ;
Belch, AR ;
Pilarski, LM .
BLOOD, 2003, 101 (04) :1520-1529
[23]   Multiple myeloma: Evolving genetic events and host interactions [J].
Kuehl, WM ;
Bergsagel, PL .
NATURE REVIEWS CANCER, 2002, 2 (03) :175-187
[24]   Novel evidence of a role for chromosome I pericentric heterochromatin in the pathogenesis of B-cell lymphoma and multiple myeloma [J].
Le Baccon, P ;
Leroux, D ;
Dascalescu, C ;
Duley, S ;
Marais, D ;
Esmenjaud, E ;
Sotto, JJ ;
Callanan, M .
GENES CHROMOSOMES & CANCER, 2001, 32 (03) :250-264
[25]   Value of comparative genomic hybridization and fluorescence in situ hybridization for molecular diagnostics in multiple myeloma [J].
Liebisch, P ;
Viardot, A ;
Bassermann, N ;
Wendl, C ;
Roth, K ;
Goldschmidt, H ;
Einsele, H ;
Straka, C ;
Stilgenbauer, S ;
Döhner, H ;
Bentz, M .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 122 (02) :193-201
[26]   A pooled analysis of karyotypic patterns, breakpoints and imbalances in 783 cytogenetically abnormal multiple myelomas reveals frequently involved chromosome segments as well as significant age- and sex-related differences [J].
Nilsson, T ;
Höglund, M ;
Lenhoff, S ;
Rylander, L ;
Turesson, I ;
Westin, J ;
Mitelman, F ;
Johansson, B .
BRITISH JOURNAL OF HAEMATOLOGY, 2003, 120 (06) :960-969
[27]   When protein destruction runs amok, malignancy is on the loose [J].
Pagano, M ;
Benmaamar, R .
CANCER CELL, 2003, 4 (04) :251-256
[28]   Bone lesions in molecular subtypes of multiple myeloma [J].
Robbiani, DF ;
Chesi, M ;
Bergsagel, PL .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (02) :197-198
[29]   Genomic instability in multiple myeloma: Evidence for jumping segmental duplications of chromosome arm Iq [J].
Sawyer, JR ;
Tricot, G ;
Lukacs, JL ;
Binz, RL ;
Tian, E ;
Barlogie, B ;
Shaughnessy, J .
GENES CHROMOSOMES & CANCER, 2005, 42 (01) :95-106
[30]   Jumping translocations of chromosome 1q in multiple myeloma: Evidence for a mechanism involving decondensation of pericentromeric heterochromatin [J].
Sawyer, JR ;
Tricot, G ;
Mattox, S ;
Jagannath, S ;
Barlogie, B .
BLOOD, 1998, 91 (05) :1732-1741